Kevin Schulman, MD, is a renowned clinical researcher and faculty member of Duke general internal medicine. This week’s issue of JAMA shows Dr. Schulman as co-author of a Viewpoint article titled “Options to Promote Competitive Generics Markets in the United States.” His colleagues are faculty from Brown University and Harvard Medical School.
Their paper is timely, not only a reaction to the recent skyrocketed pricing of pyrimethamine (Daraprim), an anti-parasitic drug, but reaction to growing shortages of generic drugs. The article lays out the market barriers, even comments on the current political landscape.
Schulman and his colleagues propose three options to stabilize the market. The paper is available to read now, published as open access.
Wiske CP, Ogbechie OA, Schulman KA. Options to Promote Competitive Generics Markets in the United States. JAMA.Published online October 29, 2015. doi:10.1001/jama.2015.13498. [Link]